Last reviewed 2026-04-22 · How we verify

Commercial Formulation Etanercept

Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.

Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.

At a glance

Mechanism of action

Etanercept consists of the extracellular ligand-binding portion of the human TNF receptor II fused to the Fc region of human IgG1. It acts as a soluble TNF receptor that competitively inhibits TNF-α and TNF-β from binding to cell surface TNF receptors, thereby suppressing TNF-mediated inflammatory responses. This mechanism reduces the activation of immune cells and production of inflammatory mediators in autoimmune and inflammatory conditions.

Approved indications

• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Juvenile idiopathic arthritis
• Plaque psoriasis
• Crohn's disease

Common side effects

• Injection site reactions
• Upper respiratory tract infections
• Headache
• Dizziness
• Serious infections
• Tuberculosis reactivation

Key clinical trials

• Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Commercial Formulation Etanercept CI brief — competitive landscape report
• Commercial Formulation Etanercept updates RSS · CI watch RSS
• Amgen portfolio CI